ArticleFrontiers in pharmacology2025
Synergistic anticancer potential of biogenic nanoparticles and cryptomeridiol from
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Marine Klebsiella sp. RR1-mediated AgNPs functionalized with matcha: synthesis, characterization, and evaluation of antibacterial, antioxidant, anti-inflammatory, and gene regulation of breast cancer potentials.Microbial cell factories · 2026Article
- An Overview of Limonoids and Other Natural Products Isolated from the Medicinal PlantPlants (Basel, Switzerland) · 2026Review
- In vitro antiproliferative effects of green synthesized silver nanoparticles from Brassica carinata microgreens on DU-145 prostate cancer cells and In vivo safety assessment.Journal, genetic engineering & biotechnology · 2025Article
- Chloroquine as a potential anticancer agent for triple-negative breast cancer: effects on MDA-MB-231 cells.Medical oncology (Northwood, London, England) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methods: The plant was collected and subjected to Soxhlet extraction using ethanol, followed by sequential solvent partitioning and silica gel column chromatography to isolate bioactive fractions. Green synthesis of AgNPs was conducted using Results: The ethanolic extract exhibited moderate cytotoxicity against HGT-1 cells, whereas biosynthesized AgNPs demonstrated enhanced anticancer activity with reduced toxicity to normal hepatocytes. The active fraction, identified as cryptomeridiol, showed the highest selectivity and potency against cancer cells. qPCR revealed significant upregulation of p21 and downregulation of CDK2, suggesting cell cycle arrest. Western blot analysis confirmed increased expression of caspase-3 and caspase-9 and a reduction in XIAP, indicating apoptosis activation. Conclusion: This study underscores the potential of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.